Ablynx is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, haematology, oncology and pulmonary disease.
The unique characteristics of Nanobodies and continuous innovation have allowed Ablynx, and its partners, to develop differentiated drug products such as both antagonistic and agonistic Nanobodies, bispecific Nanobodies, Nanobodies against challenging targets such as ion channels and GPCRs, Nanobodies that are administered through alternative routes of administration and Nanobodies half-lives which can be modulated from hours to days to weeks.
Ablynx’s Annual Report 2012 is available
Ablynx announced excellent 24 week efficacy and safety results for its anti-IL-6R Nanobody, ALX-0061, in a Phase II clinical trial in RA
Click here to replay the webcast
If you have an interest in attending one or our Shareholders Club Events, please click here